Clinical Trial Update: Crossover Study to Assess the Safety and Pharmacokinetic of Pegylated Somatropin(PEG Somatropin) in GHD Children [Phase 1]

View source ↗

Summary

A Phase 1 crossover study evaluating the safety and pharmacokinetics of pegylated somatropin in children with growth hormone deficiency has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Growth Hormone Deficiency

Drugs mentioned

• Pegylated Somatropin (PEG Somatropin) (pegylated somatropin)

Snippet

Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. | Conditions: Growth Hormone Deficiency | Phase 1 | Status: COMPLETED